Intec Pharma Granted Patent in Canada for Accordion Pill Carbidopa / Levodopa

JERUSALEM, January 3, 2018 /PRNewswire/ --

Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: NTEC), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion PillTM platform technology, today announced that the Canadian Intellectual Property Office has issued a Certificate of Grant of a Canadian patent No. 2,721,493. The patent, entitled “Carbidopa/Levodopa Gastroretentive Drug Delivery,” broadly covers the Accordion Pill containing certain drugs, including the combination of Carbidopa and Levodopa and provides patent protection through April 2029. The patent belongs to the Company’s IN-7 patent family, which already includes patents granted in the U.S., Europe, China, Japan, South Korea, Hong Kong, South Africa, and Israel.

“This patent further strengthens our global IP leadership in gastric retention drug delivery with the Accordion Pill technology platform, and we remain committed to continuing to build out our IN-7 patent family,” stated Jeffrey A. Meckler, Chief Executive Officer of Intec Pharma. “The patent secures key elements of our technology, including our leading product, the Accordion Pill Carbidopa/Levodopa, which is in a global Phase III clinical trial in advanced Parkinson’s disease. The expanded patent protection granted by the Canadian Intellectual Property Office enhances our global commercial efforts for AP-CDLD and we look forward to continuing to add to our IP position.”

About Intec Pharma Ltd.

Intec Pharma is a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology. The Company’s Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing an efficient gastric retention and specific release mechanism. The Company’s product pipeline includes two product candidates in clinical trial stages: Accordion Pill Carbidopa/Levodopa, or AP-CD/LD, which is being developed for the treatment of Parkinson’s disease symptoms in advanced Parkinson’s disease patients, and AP-CBD/THC, an Accordion Pill with the two primary cannabinoids contained in Cannabis sativa, cannabidiol (CBD) and tetrahydrocannabinol (THC), which is being developed for various indications including low back neuropathic pain and fibromyalgia.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements about the Company’s expectations, beliefs and intentions. Forward-looking statements can be identified by the use of forward-looking words such as “believe”, “expect”, “intend”, “plan”, “may”, “should”, “could”, “might”, “seek”, “target”, “will”, “project”, “forecast”, “continue” or “anticipate” or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. These forward-looking statements are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and the company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the company’s control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in the company’s filings with the Securities and Exchange Commission, and include the following: the company’s ability to develop and commercialize its product candidates and obtain additional financing necessary therefor; the length, cost and uncertain results of the company’s clinical trials; including uncertainty regarding the Company’s ability to enroll the required number of patients therein; the potential of adverse side effects, other safety risks, or legal prohibitions on the use of certain products in certain jurisdictions that could preclude the approval of the company’s drug candidates; the availability of reimbursement from government authorities and health insurance companies for the company’s products; the impact of product liability lawsuits; and the influence of extensive and costly government regulation.

 Contact: Bob Yedid LifeSci Advisors 646-597-6989 bob@lifesciadvisors.com 

SOURCE Intec Pharma Ltd.